Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 5
2017 7
2018 3
2019 1
2020 1
2021 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change.
Cash BD, Lacy BE, Watton C, Schoenfeld PS, Weissman D. Cash BD, et al. Ther Adv Gastroenterol. 2021 Apr 10;14:17562848211001725. doi: 10.1177/17562848211001725. eCollection 2021. Ther Adv Gastroenterol. 2021. PMID: 33953798 Free PMC article.
The FDA's adverse event reporting system (AERS) was also interrogated for cases of pancreatitis concomitantly reported with eluxadoline use. RESULTS: In patients who received eluxadoline, 273 reported cases of pancreatitis were recorded (total AEs n = …
The FDA's adverse event reporting system (AERS) was also interrogated for cases of pancreatitis concomitantly reported with eluxad …
Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.
Gawron AJ, Bielefeldt K. Gawron AJ, et al. Clin Gastroenterol Hepatol. 2018 Mar;16(3):378-384.e2. doi: 10.1016/j.cgh.2017.08.006. Epub 2017 Aug 10. Clin Gastroenterol Hepatol. 2018. PMID: 28804032
RESULTS: Pancreatitis accounted for 16.4% of the 597 reports of adverse events linked to eluxadoline; 53 cases required hospitalization. ...CONCLUSIONS: In an analysis of reports on eluxadoline submitted to the Federal Adverse Event Reporting System, we confi …
RESULTS: Pancreatitis accounted for 16.4% of the 597 reports of adverse events linked to eluxadoline; 53 cases required hospit …
Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE. Lacy BE. Neurogastroenterol Motil. 2016 Jan;28(1):26-35. doi: 10.1111/nmo.12716. Neurogastroenterol Motil. 2016. PMID: 26690872 Review.
Irritable bowel syndrome is categorized into one of three main categories: IBS with diarrhea, IBS with constipation, and IBS with mixed bowel habits. Patients with diarrhea-predominant IBS (IBS-D) comprise a substantial proportion of the overall …
Irritable bowel syndrome is categorized into one of three main categories: IBS with diarrhea, IBS with constipation, and IB …
Eluxadoline-induced Recurrent Pancreatitis in a Young Female without a Gallbladder: A Case Report and Literature Review.
Khetpal N, Yadav L, Khalid S, Kumar R. Khetpal N, et al. Cureus. 2018 Dec 18;10(12):e3747. doi: 10.7759/cureus.3747. Cureus. 2018. PMID: 30820368 Free PMC article.
We present a rare case of eluxadoline-induced recurrent pancreatitis in a 31-year-old female without a gallbladder. Her medical history was significant for irritable bowel syndrome with diarrhea (IBS-D), cholecystectomy, and depression. She was started on 75 …
We present a rare case of eluxadoline-induced recurrent pancreatitis in a 31-year-old female without a gallbladder. Her medica …
Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.
Keating GM. Keating GM. Drugs. 2017 Jun;77(9):1009-1016. doi: 10.1007/s40265-017-0756-7. Drugs. 2017. PMID: 28493170 Review.
The randomized, double-blind, placebo-controlled, multinational, phase 3 IBS-3001 and IBS-3002 trials examined the efficacy of eluxadoline in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D). ...Pancreatitis and adverse event …
The randomized, double-blind, placebo-controlled, multinational, phase 3 IBS-3001 and IBS-3002 trials examined the efficacy of …
New therapeutic options for IBS: the role of the first in class mixed - opioid receptor agonist and delta-opioid receptor antagonist (mudelta) eluxadoline.
Corsetti M, Whorwell P. Corsetti M, et al. Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):285-292. doi: 10.1080/17474124.2017.1298442. Epub 2017 Mar 1. Expert Rev Gastroenterol Hepatol. 2017. PMID: 28276811 Review.
Areas covered: This article focuses on eluxadoline, a novel pharmacological agent that has recently been approved by both the FDA and EMA for treatment of patients with IBS-D. ...Its positioning in any IBS algorithm will depend on the 'real world' prevalence …
Areas covered: This article focuses on eluxadoline, a novel pharmacological agent that has recently been approved by both the FDA and …
Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy.
Barshop K, Staller K. Barshop K, et al. Ther Adv Chronic Dis. 2017 Nov;8(11):153-160. doi: 10.1177/2040622317714389. Epub 2017 Jun 21. Ther Adv Chronic Dis. 2017. PMID: 29090081 Free PMC article. Review.
Eluxadoline, a - and kappa-opioid receptor agonist and delta-opioid receptor antagonist, was recently approved for the treatment of IBS-D. ...As a new drug to enter the IBS-D market, the place of eluxadoline in the hierarchy of IBS treatments i …
Eluxadoline, a - and kappa-opioid receptor agonist and delta-opioid receptor antagonist, was recently approved for the treatment of …
Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.
Scarpellini E, Laterza L, Ianiro G, Tack J, Abenavoli L, Gasbarrini A. Scarpellini E, et al. Expert Opin Pharmacother. 2016 Jul;17(10):1395-402. doi: 10.1080/14656566.2016.1182982. Epub 2016 Jun 8. Expert Opin Pharmacother. 2016. PMID: 27267380 Review.
Interestingly, eluxadoline showed a low rate of constipation development in IBS patients in comparison with known effects of other opioid receptor modulators. Patients with a history of acute pancreatitis should not be treated with eluxadoline....
Interestingly, eluxadoline showed a low rate of constipation development in IBS patients in comparison with known effects of o …
Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS. Cash BD, et al. Am J Gastroenterol. 2017 Feb;112(2):365-374. doi: 10.1038/ajg.2016.542. Epub 2016 Dec 6. Am J Gastroenterol. 2017. PMID: 27922029 Free PMC article. Clinical Trial.
This analysis evaluated the safety and tolerability of eluxadoline 75 and 100 mg twice daily (BID) in one Phase 2 (IBS-2001) and two Phase 3 (IBS-3001 and IBS-3002) studies. METHODS: Adults with IBS-D (Rome III criteria) were randomized to place …
This analysis evaluated the safety and tolerability of eluxadoline 75 and 100 mg twice daily (BID) in one Phase 2 (IBS-2001) a …
Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
Liu R, Staller K. Liu R, et al. Drug Des Devel Ther. 2020 Apr 9;14:1391-1400. doi: 10.2147/DDDT.S216056. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32308371 Free PMC article. Review.
Serious adverse events associated with eluxadoline include sphincter of Oddi spasm (SOS) and pancreatitis particularly in patients without a gallbladder. ...This adverse event profile helps guide proper selection of IBS-D patients for eluxadoline use, …
Serious adverse events associated with eluxadoline include sphincter of Oddi spasm (SOS) and pancreatitis particularly in pati …
17 results